A patient with multiple myeloma developed adenocarcinoma of the breast during treatment with melphalan, and died with acute leukemia. The role of melphalan and other possible factors which led to this course of events is discussed. The occurrence of pancytopenia (unrelated to excessive therapy) and a precipitous fall in the level of serum paraprotein, associated with clinical deterioration, may indicate the possible development of leukemia in patients with myeloma.
|Number of pages||4|
|Journal||Israel Journal of Medical Sciences|
|State||Published - 1973|